Personalized polyunsaturated fatty acids as a potential adjunctive treatment for anorexia nervosa

Betty B. Shih; Christophe Morisseau; Thu Le; Blake Woodside; Bruce J. German

doi:10.1016/j.prostaglandins.2017.08.010

Personalized polyunsaturated fatty acids as a potential adjunctive treatment for anorexia nervosa

Betty B. Shih, Christophe Morisseau, Thu Le, Blake Woodside, Bruce J. German

Entomology

Research output: Contribution to journal › Article

6 Scopus citations

Abstract

Anorexia nervosa (AN) is a complex psychiatric disorder with high morbidity and mortality rates. While many individuals make full recoveries, up to a third of patients develop a chronic, treatment-resistant form of the illness that leads to a premature death in 15-20% of those affected. There have been few advances in treatment, both in terms of psychological or pharmacologic treatment over the last 30 years. Food aversion is commonly cited by patients with AN as a barrier to normalizing eating and weight. Our group has a keen interest in examining factors that might allow this to be addressed, thus improving treatment outcomes through personalized dietary plans or nutritional supplementation related to underlying genetic status.

Original language	English (US)
Journal	Prostaglandins and Other Lipid Mediators
DOIs	https://doi.org/10.1016/j.prostaglandins.2017.08.010
State	Accepted/In press - 2017

Keywords

Anorexia nervosa
Eicosanoid
Inflammation
Mental health
Polyunsaturated fatty acid
Weight and appetite

ASJC Scopus subject areas

Physiology
Biochemistry
Pharmacology
Cell Biology

Access to Document

10.1016/j.prostaglandins.2017.08.010

Fingerprint Dive into the research topics of 'Personalized polyunsaturated fatty acids as a potential adjunctive treatment for anorexia nervosa'. Together they form a unique fingerprint.

Cite this

Shih, B. B., Morisseau, C., Le, T., Woodside, B., & German, B. J. (Accepted/In press). Personalized polyunsaturated fatty acids as a potential adjunctive treatment for anorexia nervosa. Prostaglandins and Other Lipid Mediators. https://doi.org/10.1016/j.prostaglandins.2017.08.010

@article{790ea104d0574e41a3ff28e01a1ccda9,

title = "Personalized polyunsaturated fatty acids as a potential adjunctive treatment for anorexia nervosa",

abstract = "Anorexia nervosa (AN) is a complex psychiatric disorder with high morbidity and mortality rates. While many individuals make full recoveries, up to a third of patients develop a chronic, treatment-resistant form of the illness that leads to a premature death in 15-20% of those affected. There have been few advances in treatment, both in terms of psychological or pharmacologic treatment over the last 30 years. Food aversion is commonly cited by patients with AN as a barrier to normalizing eating and weight. Our group has a keen interest in examining factors that might allow this to be addressed, thus improving treatment outcomes through personalized dietary plans or nutritional supplementation related to underlying genetic status.",

keywords = "Anorexia nervosa, Eicosanoid, Inflammation, Mental health, Polyunsaturated fatty acid, Weight and appetite",

author = "Shih, {Betty B.} and Christophe Morisseau and Thu Le and Blake Woodside and German, {Bruce J.}",

year = "2017",

doi = "10.1016/j.prostaglandins.2017.08.010",

language = "English (US)",

journal = "Prostaglandins and Other Lipid Mediators",

issn = "1098-8823",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Personalized polyunsaturated fatty acids as a potential adjunctive treatment for anorexia nervosa

AU - Shih, Betty B.

AU - Morisseau, Christophe

AU - Le, Thu

AU - Woodside, Blake

AU - German, Bruce J.

PY - 2017

Y1 - 2017

N2 - Anorexia nervosa (AN) is a complex psychiatric disorder with high morbidity and mortality rates. While many individuals make full recoveries, up to a third of patients develop a chronic, treatment-resistant form of the illness that leads to a premature death in 15-20% of those affected. There have been few advances in treatment, both in terms of psychological or pharmacologic treatment over the last 30 years. Food aversion is commonly cited by patients with AN as a barrier to normalizing eating and weight. Our group has a keen interest in examining factors that might allow this to be addressed, thus improving treatment outcomes through personalized dietary plans or nutritional supplementation related to underlying genetic status.

AB - Anorexia nervosa (AN) is a complex psychiatric disorder with high morbidity and mortality rates. While many individuals make full recoveries, up to a third of patients develop a chronic, treatment-resistant form of the illness that leads to a premature death in 15-20% of those affected. There have been few advances in treatment, both in terms of psychological or pharmacologic treatment over the last 30 years. Food aversion is commonly cited by patients with AN as a barrier to normalizing eating and weight. Our group has a keen interest in examining factors that might allow this to be addressed, thus improving treatment outcomes through personalized dietary plans or nutritional supplementation related to underlying genetic status.

KW - Anorexia nervosa

KW - Eicosanoid

KW - Inflammation

KW - Mental health

KW - Polyunsaturated fatty acid

KW - Weight and appetite

UR - http://www.scopus.com/inward/record.url?scp=85029004532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029004532&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2017.08.010

DO - 10.1016/j.prostaglandins.2017.08.010

M3 - Article

AN - SCOPUS:85029004532

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

ER -